Clinuvel/FDA To Discuss NDA For Phototoxicity Drug Scenesse
This article was originally published in Scrip
Executive Summary
The Australian company Clinuvel Pharmaceuticals is to meet the US Food and Drug Administration in late September to discuss the NDA filing requirements for its orphan drug Scenesse (afamelanotide) for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder characterized by an absolute intolerance to light.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.